Highlights Tiziana Life Sciences Ltd

Equities

TLSA

BMG889121031

Real-time Estimate Cboe BZX Other stock markets 10:12:31 2024-05-15 am EDT			5-day change	1st Jan Change
0.578 ^USD	+2.72%		-14.69%	+1.82%

May. 10	Tiziana Life Sciences Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 25	Tiziana Life Sciences Ltd Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tiziana Life Sciences Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	May. 10	CI
Tiziana Life Sciences Ltd Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	Apr. 25	CI
Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program	Apr. 23	MT
Tiziana Life Sciences, Ltd. Announces FDA Allowance for Additional Twenty Patients to Be Enroll in Intranasal Foralumab Multiple Sclerosis Expanded Access Program	Apr. 23	CI
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in Its Expanded Access Program	Apr. 22	CI
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with Pira Highlighted in Neurology	Apr. 19	CI
Tiziana Life Sciences Ltd. Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	Apr. 18	CI
Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients	Jan. 08	CI
Tiziana Life Sciences Ltd Files New Patent Application for Combination Therapy of anti-CD3 with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation	Jan. 05	CI
Tiziana Life Sciences Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	Dec. 30	CI
Tiziana Life Sciences Ltd. Doses First Patient in Phase 2A Trial of Intranasal Foralumab in Multiple Sclerosis	Dec. 19	CI
Tiziana Life Sciences Ltd. Announces Successfully Enrolled and Dosed Four New Patients with Non-Active Secondary Progressive Multiple Sclerosis	Nov. 30	CI
Tiziana Life Sciences Ltd. Announces Allowance by Fda for At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis Treatment	23-10-18	CI
Tiziana Life Sciences Ltd. Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab	23-10-16	CI
Tiziana Announces Positive Qualitative Six-Month Pet Scan Results with Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed with Non-Active Secondary Progressive MS (Na-SPMS)	23-10-13	CI
Tiziana Life Sciences Ltd. Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis	23-09-26	CI
BMW expects higher China sales in 2023, finance chief says	23-09-02	RE
Tiziana Life Sciences Says US FDA Cleared IND Application for Investigational Alzheimer's Drug	23-08-15	MT
Tiziana Life Sciences Ltd. Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer's Disease	23-08-15	CI
Tiziana Life Sciences Gets Nasdaq Notice on Minimum Bid Price Deficiency	23-07-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Tiziana Life Sciences Ltd

Equities

TLSA

BMG889121031

Highlights

Filters